Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND AIM: Strategies to reduce relapse using immunomodulators (IMs) after discontinuing anti-tumor necrosis factor-alpha (TNF-α) antibody treatment are controversial in patients with ulcerative colitis (UC). In this study, we assessed the association between IMs after discontinuing anti-TNF-α antibody treatment and relapse in patients with UC. METHODS: This retrospective, multicenter cohort study included 257 patients with UC in clinical remission. These patients discontinued anti-TNF-α antibody treatment between June 2010 and March 2019 and were followed up until March 2020. We evaluated the differences in relapse rates between patients with IMs (IM group) and those without IMs (non-IM group) after discontinuing the treatment. Relapse was defined as further undergoing an induction treatment or colectomy. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for relapse. Exploratory analyses were performed to identify other factors that could predict relapse. RESULTS: During the median follow-up period of 22 months (interquartile range: 10-41), 114 relapses occurred: 42/100 (42.0%) in the IM group and 72/157 (45.9%) in the non-IM group. In the multivariable analysis, IMs were not associated with relapse (HR, 0.95 [95% CI, 0.64-1.41]). In the exploratory analyses, discontinuation due to side effects (HR, 1.83 [95% CI, 1.18-2.82]) and younger age (HR, 0.99 [95% CI, 0.98-1.00]) predicted relapse. CONCLUSION: Immunomodulators were not associated with relapse after discontinuing anti-TNF-α antibody treatment in patients with UC. Careful patient follow-up is needed when discontinuing due to side effects or when the patient is of a younger age at the time of discontinuation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study
- Date Crossref
- 12/10/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
SHOWA Medical University Fujigaoka Hospital pays non établi dans la noticeÉtablissement de santé
-
Nagoya City University Department of Gastroenterology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
Kyoto University Section of Clinical Epidemiology pays non établi dans la noticeUniversité ou école supérieure
-
Japan Community Healthcare Organization Center for Inflammatory Bowel Disease pays non établi dans la noticeOrganisme public
-
Tokyo Yamate Medical Center Center for Inflammatory Bowel Disease pays non établi dans la noticeÉtablissement de santé
-
Kyorin University Department of Gastroenterology and Hepatology pays non établi dans la noticeUniversité ou école supérieure
-
Keio University Division of Gastroenterology and Hepatology pays non établi dans la noticeUniversité ou école supérieure
-
University of Miyazaki Hospital Department of Gastroenterology and Hepatology pays non établi dans la noticeÉtablissement de santé
-
Kitasato Institute Hospital Center for Advanced IBD Research and Treatment pays non établi dans la noticeÉtablissement de santé
-
Kitasato University pays non établi dans la noticeUniversité ou école supérieure
-
Toyohashi Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Yokohama City University Medical Center Inflammatory Bowel Disease Center pays non établi dans la noticeÉtablissement de santé
SHOWA Medical University Fujigaoka Hospital, Department of Gastroenterology and Metabolism — Nagoya City University et Section of Clinical Epidemiology — Kyoto University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.